In a recent actualization of the International Consensus Classification (ICC) 2022 AML and the World Health Organization (WHO) 2022 classification, TP53 mutant (TP53mut) AML and myelodysplastic syndromes (MDS) have been individualized based on their poor prognosis [33,34]. This evidence concerns the gene TP53 and myelodysplastic syndrome.